Last week, a federal appeals court in Maryland ruled that a law, passed in 2017 and aimed at combatting increases in the price of generic medicines, is unconstitutional.
Last week, a federal appeals court in Maryland ruled that a law, passed in 2017 and aimed at combatting increases in the price of generic medicines, is unconstitutional.
The Association for Accessible Medicines (AAM) filed a suit against the state in a US district court in Maryland last year, alleging that the bill grants the state “unprecedented powers to regulate the national pharmaceutical market, violating the [US] Constitution and posing harm to vulnerable patient communities.”
The bill targeted “price gouging” in the sale of off-patent or generic drugs by requiring the Maryland Medical Assistance Program to notify the state’s attorney general of an increase in the prices of such medicines. In addition, it authorized the attorney general to require a drug manufacturer to turn over its records concerning the drug, and permitted a circuit court to compel action or impose penalties of up to $10,000 per infraction on the drug manufacturer.
In a 2 to 1 ruling, the 4th Circuit Court of Appeals found that the law would regulate trade beyond Maryland’s borders, which violates the so-called dormant commerce clause. Judge Stephanie D. Thacker wrote an opinion that ordered a lower-level federal judge to bar the law from taking effect.
“Maryland cannot, even in an effort to protect its consumers from skyrocketing prescription drug costs, impose its preferences in this manner,” wrote Judge Thacker.
This ruling comes as a disappointment for Maryland Attorney General Brian Frosh, who supported the bill and helped get it passed in the General Assembly in 2017.
“We remain committed to pursuing efforts to eliminate price gouging and to safeguarding Marylanders’ access to prescription drugs,” Frosh told The Baltimore Sun.
The president of the AAM, Chip Davis Jr., JD, was pleased with the outcome, saying in a statement that, “As AAM has always maintained, this law, and any others modeled from it, would harm patients because the law would reduce generic drug competition and choice, thus resulting in an overall increase in drug costs due to increased reliance upon more costly branded medications."
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.